about
Receptor-binding domain-based subunit vaccines against MERS-CoVAdvancements in the development of subunit influenza vaccinesRational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations.Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitorPolyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infectionMERS-CoV spike protein: a key target for antivirals.Receptor-binding domain as a target for developing SARS vaccines.Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread.Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.Enhancement of endocytic uptake of HIV-1 virions into CD4-negative epithelial cells by HIV-1 gp41 via its interaction with POB1Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entrySmall molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infectionsReceptor binding domain based HIV vaccines.Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infectionNonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy.ADS-J1 inhibits semen-derived amyloid fibril formation and blocks fibril-mediated enhancement of HIV-1 infection.Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV InfectionCharacterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and DiseaseA bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.Respiratory syncytial virus entry inhibitors targeting the F protein.Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41Controlling HIV sexual transmission: a major challenge for China's new leadership.Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines.Biosecurity and biosafety in research on emerging pathogensAn immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter geneSite-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection.Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocketMiddle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein.Adenovirus-based vaccines against avian-origin H5N1 influenza viruses.Development of therapeutics for treatment of Ebola virus infection.Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy.Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.HIV-1 impairs human retinal pigment epithelial barrier function: possible association with the pathogenesis of HIV-associated retinopathy.
P50
Q26851979-186C8CBC-3108-4809-B378-655F97AB3721Q27010100-78948281-DCFE-47C1-B1EA-1A066ECDF4A1Q27315206-29251F1A-C815-4641-97A0-77A49921406EQ27689029-622452FB-F996-4973-B119-F6E198EBAD97Q28489042-655B0999-291A-4A49-BF2A-1CF7D6848880Q30240139-CD8D9107-0CF3-4199-B373-B2014D526A1CQ30353170-A4C13933-9F96-4514-ABF9-A45B7DFF5DA4Q30362113-5D247C15-0E87-4E08-9C11-3FDE1F066426Q30371303-BBC5EA19-2A33-479E-A068-F8E439B999F6Q30432264-DD523EE2-B2C5-4BE9-8201-817BAD1A6919Q30432706-66CA34F6-FB6B-450F-81CE-4EDDFB2B4C92Q33654409-DDC4C2DE-7473-40D5-B449-F1985FB23B6BQ33920132-A05C9982-3E1E-424B-A768-2E452D47CB44Q34062476-1BB5A957-6800-41A1-8D20-066096FACFD7Q34412839-DB47794E-1D75-48F4-B032-B373B82CD0D7Q34722246-6DAD29D0-1618-42BE-BA66-B54682BA75E7Q34761552-77A86893-1A33-48D9-B69F-576006E01C9FQ35019893-5A18E7FC-E33E-40E6-8007-72B24BAA717FQ35033862-A74B5230-C64E-4A33-AA50-5D8CD01CD3B5Q35160026-2101E92D-8477-4CFC-B866-3A116BE20EE1Q35745350-34E0EBCB-0C64-467D-A49D-0172D6D8F932Q35960654-8AB5FEBA-E153-4F5C-8B77-536E45F1627EQ36306931-54005FE2-74B5-4F4F-8C2D-1060AD498C2DQ36433987-9C6D3FB2-C846-4B20-A6A8-23E0DD9D7BF5Q36491733-AA0ED4FB-2E8B-49E0-A038-0D6998F42DF8Q36586879-8B628CC8-E51A-4915-A085-8E6A76AFC906Q36643050-A4C0AAE1-1690-483B-94BE-C8E7724655FDQ36753351-CCB913CC-6780-4CCB-A939-2F8400794F94Q36779713-B33FE923-A8A0-4526-AA45-1CBD186267C0Q36779741-C8BC020C-74CD-4B38-9CF3-750621AD7966Q37064315-CF7E5FCA-57BE-4148-9293-D872563B8C44Q37209050-3AE48FE3-0B22-4DA6-AB73-7B93C72C33C9Q37512905-DBF4887E-A113-454C-80BF-20F69423EBB6Q38076321-3DE1CD93-F377-4652-91F4-3CFA2D214CC1Q38275793-1FEEDF6F-C6A0-4C26-BE31-CB8C055599E8Q38283820-E1534925-BFB6-438C-9AFB-493A664C38D7Q38286766-EE532145-4A24-4309-8C11-310FBE065B42Q38817623-F07EC504-9D65-4E61-937B-48CC3A17BCC4Q38979759-32B5943E-5916-4A09-85A5-215CA43A7B47Q38993792-53A95F82-F707-471D-B105-3B62C12C6464
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lu Lu
@ast
Lu Lu
@en
Lu Lu
@es
Lu Lu
@nl
Lu Lu
@sl
type
label
Lu Lu
@ast
Lu Lu
@en
Lu Lu
@es
Lu Lu
@nl
Lu Lu
@sl
prefLabel
Lu Lu
@ast
Lu Lu
@en
Lu Lu
@es
Lu Lu
@nl
Lu Lu
@sl
P106
P31
P496
0000-0002-2255-0391